{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T04:41:42Z","timestamp":1789101702276,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.clgc.2024.102275","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T11:34:26Z","timestamp":1732275266000},"page":"102275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Complex Decision Making for Individual Patients With Penile Cancer: Benchmarking Divergent Practices in European High-Volume Reference Centers: Results From eUROGEN Survey"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7516-8762","authenticated-orcid":false,"given":"Laura","family":"Elst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1515-3825","authenticated-orcid":false,"given":"Darren","family":"Shilhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Battye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jure","family":"Murgi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5834-9841","authenticated-orcid":false,"given":"Ana","family":"Fr\u04e7be","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Albersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-3636","authenticated-orcid":false,"given":"Marija","family":"Mileti\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.clgc.2024.102275_bib0001","doi-asserted-by":"crossref","first-page":"578.e11","DOI":"10.1016\/j.urolonc.2019.05.024","article-title":"Adherence to guideline recommendations for lymph node dissection in squamous cell carcinoma of the penis: effect on survival and complication rates","volume":"37","author":"Mistretta","year":"2019","journal-title":"Urolog Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102275_bib0002","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2017.5608","article-title":"Treatment trends and outcomes for patients with lymph node\u2013Positive cancer of the penis","volume":"4","author":"Joshi","year":"2018","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2024.102275_bib0003","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s00345-018-2549-3","article-title":"Adherence to EAU guidelines on penile cancer translates into better outcomes: a multicenter international study","volume":"37","author":"Cindolo","year":"2019","journal-title":"World J Urol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102275_bib0004","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S0022-5347(17)35221-7","article-title":"Squamous cell carcinoma of the penis. IV. Prognostic factors of survival: analysis of tumor, nodes and metastasis classification system","volume":"151","author":"Horenblas","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2024.102275_bib0005","article-title":"Trends in incidence, mortality, and survival of penile cancer in the United States: a population-based study","volume":"12","author":"Deng","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102275_bib0006","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-021-00246-5","article-title":"Penile cancer","volume":"7","author":"Thomas","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.clgc.2024.102275_bib0007","unstructured":"National Comprehensive Cancer Network. NCCN guidelines on penile cancer. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/penile.pdf."},{"issue":"6","key":"10.1016\/j.clgc.2024.102275_bib0008","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.eururo.2023.02.027","article-title":"European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 update","volume":"83","author":"Brouwer","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102275_bib0009","doi-asserted-by":"crossref","first-page":"vi115","DOI":"10.1093\/annonc\/mdt286","article-title":"Penile cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Van Poppel","year":"2013","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2024.102275_bib0010","doi-asserted-by":"crossref","first-page":"531.e9","DOI":"10.1016\/j.urolonc.2017.03.002","article-title":"Disparity between pre-existing management of penile cancer and NCCN guidelines","volume":"35","author":"Campbell","year":"2017","journal-title":"Urolog Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2024.102275_bib0011","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1007\/s00345-019-03052-7","article-title":"Adherence to the EAU guideline recommendations for systemic chemotherapy in penile cancer: results of the E-PROPS study group survey","volume":"38","author":"Distler","year":"2020","journal-title":"World J Urol"},{"issue":"4","key":"10.1016\/j.clgc.2024.102275_bib0012","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.euf.2020.02.005","volume":"7","author":"Suarez-Ibarrola","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.clgc.2024.102275_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.759362","article-title":"Does the identification of a minimum number of cases correlate with better adherence to international guidelines regarding the treatment of penile cancer? Survey results of the European PROspective penile cancer study (E-PROPS)","volume":"11","author":"Lebentrau","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102275_bib0014","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.euf.2023.07.003","article-title":"Impact of the standardization of penile cancer care on the quality of care, outcomes, and academic-driven centralization in a single eUROGEN referral center","volume":"10","author":"Pecoraro","year":"2024","journal-title":"Eur Urol Focus"},{"issue":"6","key":"10.1016\/j.clgc.2024.102275_bib0015","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00345-019-02866-9","article-title":"Albersen M, and in collaboration with the European Reference Network for rare urogenital diseases and complex conditions (eUROGEN). Making surgery safer by centralization of care: impact of case load in penile cancer","volume":"38","author":"Vanthoor","year":"2020","journal-title":"World J Urol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102275_bib0016","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/bju.16306","article-title":"Penile cancer care in the Netherlands: increased incidence, centralisation, and improved survival","volume":"133","author":"Vreeburg","year":"2024","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.clgc.2024.102275_bib0017","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.euo.2018.10.006","article-title":"Impact of centralizing care for genitourinary malignancies to high-volume providers: a systematic review","volume":"2","author":"Williams","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102275_bib0018","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.eururo.2014.10.017","article-title":"EAU Guidelines on penile cancer: 2014 update","volume":"67","author":"Hakenberg","year":"2015","journal-title":"European Urol"},{"issue":"6","key":"10.1016\/j.clgc.2024.102275_bib0019","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/JU.0000000000000746","article-title":"Systematic review and meta-analysis\u2014is there a benefit in using neoadjuvant systemic chemotherapy for locally advanced penile squamous cell carcinoma?","volume":"203","author":"Azizi","year":"2020","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102275_bib0020","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.clgc.2014.06.005","article-title":"Neoadjuvant taxane-based combination chemotherapy in patients with advanced penile cancer","volume":"13","author":"Djajadiningrat","year":"2015","journal-title":"Clin Genitourin Cancer"},{"issue":"24","key":"10.1016\/j.clgc.2024.102275_bib0021","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.2010.29.5477","article-title":"Neoadjuvant Paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study","volume":"28","author":"Pagliaro","year":"2010","journal-title":"JCO"},{"issue":"5","key":"10.1016\/j.clgc.2024.102275_bib0022","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.euf.2019.05.010","article-title":"The International Penile advanced Cancer Trial (InPACT): rationale and current status","volume":"5","author":"Canter","year":"2019","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1016\/j.clgc.2024.102275_bib0023","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.eururo.2018.04.003","article-title":"Risks and benefits of adjuvant radiotherapy after inguinal lymphadenectomy in node-positive Penile Cancer: A systematic review by the European Association of Urology Penile Cancer Guidelines Panel","volume":"74","author":"Robinson","year":"2018","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.clgc.2024.102275_bib0024","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/bju.15309","article-title":"Long-term multicentre experience of adjuvant radiotherapy for pN3 squamous cell carcinoma of the penis","volume":"128","author":"Ager","year":"2021","journal-title":"BJU Int"},{"issue":"7","key":"10.1016\/j.clgc.2024.102275_bib0025","doi-asserted-by":"crossref","first-page":"641.e9","DOI":"10.1016\/j.urolonc.2020.03.026","article-title":"Adjuvant radiation compares favorably to chemotherapy in patients with carcinoma penis and nodal positivity restricted to groin","volume":"38","author":"Jaipuria","year":"2020","journal-title":"Urolog Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102275_bib0026","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.euo.2020.10.011","article-title":"Association between Human papillomavirus infection and outcome of perioperative nodal radiotherapy for penile carcinoma","volume":"4","author":"Bandini","year":"2021","journal-title":"Eur Urolog Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102275_bib0027","doi-asserted-by":"crossref","first-page":"200.e11","DOI":"10.1016\/j.urolonc.2022.02.014","article-title":"Effectiveness and safety of adjuvant chemotherapy compared to neoadjuvant chemotherapy in patients with penile cancer and positive lymph nodes regarding overall survival and free disease survival: a systematic review and meta-analysis","volume":"40","author":"Paz Rojas","year":"2022","journal-title":"Urolog Oncol"},{"issue":"31","key":"10.1016\/j.clgc.2024.102275_bib0028","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1200\/JCO.22.02894","article-title":"Atezolizumab with or without radiotherapy for advanced squamous cell carcinoma of the penis (The PERICLES Study): a phase II trial","volume":"41","author":"De Vries","year":"2023","journal-title":"JCO"},{"issue":"31","key":"10.1016\/j.clgc.2024.102275_bib0029","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1200\/JCO.20.01652","article-title":"Phase I study of Cabozantinib and Nivolumab alone or with Ipilimumab for advanced or metastatic urothelial carcinoma and other genitourinary tumors","volume":"38","author":"Apolo","year":"2020","journal-title":"JCO"},{"issue":"6","key":"10.1016\/j.clgc.2024.102275_bib0030","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/cncr.33328","article-title":"Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies","volume":"127","author":"McGregor","year":"2021","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.clgc.2024.102275_bib0031","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/jnci\/djad155","article-title":"Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors","volume":"115","author":"El Zarif","year":"2023","journal-title":"JNCI"},{"issue":"1","key":"10.1016\/j.clgc.2024.102275_bib0032","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ijrobp.2023.03.066","article-title":"A prospective study of chemoradiotherapy as primary treatment in patients with locoregionally advanced penile carcinoma","volume":"117","author":"Ottenhof","year":"2023","journal-title":"Int J Radiation Oncol *Biol *Phys"},{"issue":"11","key":"10.1016\/j.clgc.2024.102275_bib0033","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324002453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324002453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T15:20:34Z","timestamp":1753111234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324002453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1558767324002453"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102275","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complex Decision Making for Individual Patients With Penile Cancer: Benchmarking Divergent Practices in European High-Volume Reference Centers: Results From eUROGEN Survey","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102275","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102275"}}